Kairos Pharma, Ltd. (NYSE American: KAPA) has filed a Current Report on Form 8-K disclosing three amendments to a previously announced purchase agreement with Helena Global Investment Opportunities I Ltd. The amendments modify the terms of an equity line of credit established between the two parties.
According to the filing, the original Purchase Agreement was executed on November 12, 2024. The first amendment, executed on February 4, 2026, adjusted the purchase price for the equity line to 97% of the average daily Volume Weighted Average Price (VWAP) during the Pricing Period.
The second amendment, executed on October 26, 2026, shortened the applicable Pricing Period from three Trading Days to one Trading Day. The third amendment, executed on October 29, 2026, extended the option to utilize the equity line of credit for an additional year, extending the termination date to December 31, 2028.
In addition to the amendments to the financial agreement, the company reported that on November 3, 2026, it issued a press release announcing that President and Chief Scientific Officer Neil Bhowmick would present interim efficacy data from clinical trials evaluating ENV-105 (carotuximab) at the United Scientific Group’s 11th International Conference on Cancer Research & Drug Development in Houston, Texas.
